
    
      The purpose of this study is to determine, through serotype-specific enzyme linked
      immunosorbent assay (ELISA) and opsonophagocytosis (OPA) titres whether AAV patients who have
      gone through pneumococcal vaccination are protected against invasive pneumococcal diseases
      (IPD).
    
  